Publications by authors named "Ofer Agid"

Claim this Profile
T
The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment.
John M Kane, Ofer Agid, David J Castle, Leslie Citrome, Andrea Fagiolini

Neurol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo versus no treatment for people with schizophrenia: A systematic review and meta-analysis.
Nobuyuki Nomura, Yutaro Shimomura, Yuhei Kikuchi, Emily Hird, Hui Wu, Ofer Agid

PCN Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic discontinuation in schizophrenia: rational or reckless?
Robert B Zipursky, Ofer Agid, Gary Remington

Schizophrenia (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.
Oliver D Howes, Bernard R Bukala, Eric Y H Chen, Christoph U Correll, Alkomiet Hasan, Ofer Agid

Am J Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reassessing the evidence: does CBT truly benefit individuals with treatment-resistant schizophrenia?
Ofer Agid

Evid Based Nurs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée.
Robert B Zipursky, Ofer Agid, Michael Kiang, Gary Remington

Can J Psychiatry· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for switching central nervous system and psychiatric medication products: A review of the literature.
Ric M Procyshyn, Martin A Katzman, Howard C Margolese, Ofer Agid, Pierre M Blier

J Psychopharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Impairment and Dose Adjustment of Long-Acting Injectable Antipsychotics: Are We Getting It Right? A Case Report.
Colette Raphaël, Gary Remington, Ofer Agid

Focus (Am Psychiatr Publ)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment.
Ofer Agid

Expert Rev Neurother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice.
Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini, Oliver D Howes

Eur Neuropsychopharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of venlafaxine on anhedonia and amotivation in patients with major depressive disorder.
Roger S McIntyre, Ofer Agid, Egbert Biesheuvel, Pradeep Purushottamahanti

CNS Spectr· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol.
Sri Mahavir Agarwal, Joel Dissanayake, Ofer Agid, Christopher Bowie, Noah Brierley

PLoS One· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second version of Brief Evaluation of Psychosis Symptom Domains (BE-PSD-V2.0).
Hiroyoshi Takeuchi, Jimmy Lee, Gagan Fervaha, Ofer Agid, Gary Remington

Schizophr Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Who has poor insight, my patient suffering from schizophrenia or myself?
Michael Davidson, Ofer Agid

Eur Neuropsychopharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired insight into illness is unrelated to subjective happiness, success, and life satisfaction in schizophrenia.
Julia Kim, Laura Romero, Yusuke Iwata, Fernando Caravaggio, Gary Remington, Ofer Agid

Ann Clin Psychiatry· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.
C U Correll, Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini

CNS Drugs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.
C U Correll, Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini

CNS Drugs· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study.
Ofer Agid, Gary Remington, Carmen Fung, Natalie M Nightingale, Marc Duclos

Can J Psychiatry· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When No Treatment Is the Treatment: Mental Illness-Related Case Report.
Colette Raphaël, Ofer Agid

Can J Hosp Pharm· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia.
Daniel Krzyzanowski, Ofer Agid, Vina Goghari, Gary Remington

Schizophr Res Cogn· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications.
Hiroyoshi Takeuchi, Marcos Sanches, Carol Borlido, Ofer Agid, Gary Remington

Schizophr Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Schizophrenia: Antipsychotics and drug development.
Gary Remington, Margaret K Hahn, Sri Mahavir Agarwal, Araba Chintoh, Ofer Agid

Behav Brain Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic Medications: Enhancing Use to Improve Outcomes.
Hiroyoshi Takeuchi, Stefan Leucht, John M Kane, Ofer Agid, Gary Remington

Schizophr Bull· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research.
Steven G Potkin, John M Kane, Christoph U Correll, Jean-Pierre Lindenmayer, Ofer Agid

Focus (Am Psychiatr Publ)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis